entertainment -WSS

entertainment

author：hotspot 2025-08-11 09:47:46 - browse：64

What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Medical records are filled with copy
Next article： The a glaring gap in research on serious mental illness and primary care

WSS

Hospitals consider fixing cancer drug shortages on their own

Popular nasal decongestant doesn't actually relieve congestion

Telehealth for opioid use disorder is lifesaving

IRA could hurt research into orphan drugs for rare diseases

How to ethically and practically extend health care to all

New weight loss drugs vying to be the next Wegovy or Mounjaro

knowledge

entertainment

hotspot

The cancer drug shortage isn’t new — and neither are the solutions

Flint parents haunted by uncertainty, fears of lead poisoning

Continuity nursing helped my family in our darkest PICU moments

Hospitals consider fixing cancer drug shortages on their own

Walensky prepares to leave CDC — and Congress — behind

Food makers to regulators: Ultra

In age of alternative facts, a scholarly course on calling out crap

FDA panel endorses Alnylam’s heart drug — after picking it apart

Drug repurposing or repositioning? The language matters

Judge partially blocks Texas abortion ban for medical emergencies, fatal diagnoses

hotspot

Chris Christie meets with Zelenskyy during Ukraine trip

Biotech startup Celsius cuts 75% of staff ahead of first trial start

Late stage cancers on the rise after pandemic delayed screenings

New weight loss drugs vying to be the next Wegovy or Mounjaro

Physicians aren't 'burning out.' They're suffering from moral injury

'Null' research findings aren't empty of meaning. Let's publish them

leisure time

hotspot

explore

hotspot